- Raised $55M funding round, Apr 2021
- Raised $22M funding round led by Sands Capital, Jan 2022
- Raised $5.4M funding round, Jun 2014
About
Nucleix is a liquid biopsy company revolutionizing cancer treatment with earlier disease detection at a time when intervention can bring the greatest impact for patients. Leveraging NGS-based and PCR-based technology to identify methylation changes, the Company’s pioneering testing approach uses methylation-based identification for early-stage and recurring cancer detection. The Company’s non-invasive EpiCheck® delivers highly accurate and sensitive results, all while providing a seamless testing option for physicians, patients, and the healthcare system. The Company is building an EpiCheck® franchise, beginning with the Bladder EpiCheck® kit, CE-marked and available in Europe for primary and recurrent bladder cancer and upper tract urinary cancer, and FDA 510(k) cleared for bladder cancer recurrence in the United States. The Company is advancing its Lung EpiCheck® test towards commercialization for high-risk individuals, while evaluating additional tests for other high-risk diseases.
Funding history · 5 rounds · $88.3M total
Q&A
- What is Nucleix's primary focus?
- Nucleix is a liquid biopsy company focused on noninvasive testing for the early detection of cancer, leveraging NGS-based and PCR-based technology to identify methylation changes.
- Which of Nucleix's products are currently available and where?
- Nucleix's Bladder EpiCheck® kit is CE-marked and available in Europe for primary and recurrent bladder cancer and upper tract urinary cancer. It is also FDA 510(k) cleared for bladder cancer recurrence in the United States.
- What is the status of Nucleix's Lung EpiCheck® test?
- Nucleix is advancing its Lung EpiCheck® test towards commercialization for high-risk individuals.
- When was Nucleix founded?
- Nucleix was founded in May 2008.
- What was Nucleix's most recent funding round?
- In January 2022, Nucleix raised $22,000,000 in a funding round led by Sands Capital, with participation from.
- What is Nucleix's total funding raised to date?
- Nucleix has raised a total of $88,300,000 across all funding rounds.
- Where are Nucleix's main offices located?
- Nucleix has its headquarters in Rehovot, Israel, with additional offices in Modi'in-Maccabim-Re'ut, Israel, and San Diego, USA.
Team · 2
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | nucleix.com |
|---|---|
| linkedin.com/company/1670969 | |
| facebook.com/Nucleix-100608201471224 | |
| YouTube | youtube.com/channel/UCZ-2RIVy9QbNCsko6S3L1Kw |
| Wikidata | wikidata.org/wiki/Q50038748 |
Identifiers & details
| Founded | 2008-5 |
|---|---|
| Employees (exact) | 69 |
| Offices | San Diego; Modi'in-Maccabim-Re'ut |
| Wikidata QID | Q50038748 |
Radar intelligence
Patents
| EPO | 31 |
|---|
Publications (Crossref)
| Works | 3 |
|---|
Web history (Wayback)
| Domain | nucleix.com |
|---|
Wikidata
| QID | Q50038748 |
|---|